CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+7.53%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.07B
AUM Growth
+$162M
(+18%)
Cap. Flow
+$137M
Cap. Flow
% of AUM
12.79%
Top 10 Holdings %
Top 10 Hldgs %
37.33%
Holding
532
New
105
Increased
323
Reduced
47
Closed
36
Top Buys
| 1 |
Apple
AAPL
|
+$9.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$7.06M |
| 3 |
NVIDIA
NVDA
|
+$6.46M |
| 4 |
Microsoft
MSFT
|
+$6.23M |
| 5 |
ProShares Ultra Gold
UGL
|
+$5.73M |
Top Sells
| 1 |
Alibaba
BABA
|
+$5.72M |
| 2 |
GSK
GSK
|
+$5.14M |
| 3 |
Pinduoduo
PDD
|
+$3.46M |
| 4 |
Procter & Gamble
PG
|
+$2.91M |
| 5 |
Synopsys
SNPS
|
+$2.45M |
Sector Composition
| 1 | Technology | 38.06% |
| 2 | Healthcare | 25.43% |
| 3 | Consumer Discretionary | 12.38% |
| 4 | Communication Services | 10.24% |
| 5 | Financials | 3.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Annexon
ANNX
$243M
| $116K | 0.01% |
+22,602
| New | +$116K |
|
377
Hertz
HTZ
$1.86B
| $114K | 0.01% |
+31,200
| New | +$114K |
|
378
Savara
SVRA
$665M
| $112K | 0.01% |
36,390
+4,732
| +15% | +$14.5K |
|
379
Tourmaline Bio
TRML
$775M
| $110K | 0.01% |
5,437
+505
| +10% | +$10.2K |
|
380
Pacific Biosciences
PACB
$375M
| $110K | 0.01% |
59,988
+5,653
| +10% | +$10.3K |
|
381
Altimmune
ALT
$327M
| $109K | 0.01% |
+15,081
| New | +$109K |
|
382
MindMed
MNMD
$714M
| $108K | 0.01% |
+15,549
| New | +$108K |
|
383
EyePoint Pharmaceuticals
EYPT
$941M
| $108K | 0.01% |
14,472
+4,179
| +41% | +$31.1K |
|
384
Xeris Biopharma Holdings
XERS
$1.25B
| $107K | 0.01% |
31,611
+2,954
| +10% | +$10K |
|
385
Astria Therapeutics
ATXS
$419M
| $107K | 0.01% |
+11,966
| New | +$107K |
|
386
CorMedix
CRMD
$952M
| $104K | 0.01% |
+12,866
| New | +$104K |
|
387
ChargePoint
CHPT
$253M
| $102K | 0.01% |
4,750
| – | – |
|
|
VERV
388
DELISTED
Verve Therapeutics
VERV
| $101K | 0.01% |
17,952
+1,676
| +10% | +$9.45K |
|
389
MeiraGTx Holdings
MGTX
$601M
| $101K | 0.01% |
16,571
+1,685
| +11% | +$10.3K |
|
390
Terns Pharmaceuticals
TERN
$637M
| $99.8K | 0.01% |
18,010
+4,475
| +33% | +$24.8K |
|
|
AUTL
391
Autolus Therapeutics
AUTL
$381M
| $99.5K | 0.01% |
42,345
+3,952
| +10% | +$9.29K |
|
|
THRD
392
DELISTED
Third Harmonic Bio
THRD
| $98.3K | 0.01% |
9,554
+1,650
| +21% | +$17K |
|
393
Theravance Biopharma
TBPH
$701M
| $98.1K | 0.01% |
10,427
+1,018
| +11% | +$9.58K |
|
394
Arcturus Therapeutics
ARCT
$484M
| $97.5K | 0.01% |
5,744
+543
| +10% | +$9.22K |
|
395
Cartesian Therapeutics
RNAC
$265M
| $96.5K | 0.01% |
+5,389
| New | +$96.5K |
|
396
UroGen Pharma
URGN
$991M
| $95.3K | 0.01% |
8,948
+848
| +10% | +$9.03K |
|
397
HUTCHMED
HCM
$2.77B
| $94.8K | 0.01% |
6,577
+611
| +10% | +$8.81K |
|
398
Allogene Therapeutics
ALLO
$253M
| $94.7K | 0.01% |
44,458
+4,239
| +11% | +$9.03K |
|
399
Zevra Therapeutics
ZVRA
$468M
| $94.4K | 0.01% |
+11,318
| New | +$94.4K |
|
400
Alpha Teknova
TKNO
$233M
| $94.4K | 0.01% |
+11,303
| New | +$94.4K |
|